Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and AspirinA Randomized Controlled Trial
Authors:
- Michael A. BlazingMBMichael A. Blazing
- James A. de LemosJLJames A. de Lemos
- Harvey D. WhiteHWHarvey D. White
- Keith A. A. FoxKFKeith A. A. Fox
- Freek W. A. VerheugtFVFreek W. A. Verheugt
- Diego ArdissinoDADiego Ardissino
- Peter M. DiBattistePDPeter M. DiBattiste
- Joanne PalmisanoJPJoanne Palmisano
- David W. BilheimerDBDavid W. Bilheimer
- Steven M. SnapinnSSSteven M. Snapinn
- Karen E. RamseyKRKaren E. Ramsey
- Laura H. GardnerLGLaura H. Gardner
Open Access
- 7 July 2004
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (1) , 55-64
Abstract
In recent years, several classes of antiplatelet and antithrombotic agents have been shown to be safe and effective therapies for patients with non–ST-segment elevation acute coronary syndromes (ACS).1 Guidelines from the American College of Cardiology, American Heart Association, and European Society of Cardiology recommend early use of small-molecule platelet glycoprotein IIb/IIIa inhibitors with unfractionated heparin in high-risk patients with non–ST-segment elevation ACS, particularly if an invasive approach is planned.2,3Keywords
This publication has 12 references indexed in Scilit:
- Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor EptifibatideCirculation, 2003
- Management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2002
- ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary articleJACC, 2002
- Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II studyAmerican Heart Journal, 2002
- An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUSEuropean Heart Journal, 2002
- The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapyAmerican Heart Journal, 2001
- Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofibanThe Lancet, 1999
- Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial InfarctionCirculation, 1999
- Platelet Activation With Unfractionated Heparin at Therapeutic Concentrations and Comparisons With a Low-Molecular-Weight Heparin and With a Direct Thrombin InhibitorCirculation, 1998
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995